Skip to main content

Table 1 Patient and tumor characteristics

From: Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study

Characteristic Chemotherapy No chemotherapy P-value
(n = 3703) (n = 232)
Age, years
 Mean (range) 55.6 (20–100) 58.3 (27–87) 0.0008
  < 60, n (%) 2298 (62) 128 (55)  
 60– 69, n (%) 971 (26) 58 (25)  
  ≥ 70, n (%) 461 (12) 46 (20)  
ECOG performance status, n (%)
 0 2301 (63) 108 (47) <0.0001
 1 1298 (35) 113 (50)  
 2–4 61 (2) 7 (3)  
Primary tumor stage, n (%)
 pT1/is 1750 (50) 114 (51) 0.73
 pT2-4 1776 (50) 110 (49)  
Lymph node stage, n (%)
 pN0 1936 (52) 126 (54)  
 pN1 1003 (27) 53 (23)  
 pN2 411 (11) 28 (12)  
 pN3 259 (7) 13 (6)  
 NX 82 (2) 12 (5)  
No. of nodes involved, mean ± SD 2.2 ± 4.7 2.3 ± 5.1 0.63
Grading, n (%)
 Grade 1/2 1731 (47) 123 (55) 0.028
 Grade 3 1927 (53) 101 (45)  
Hormone-receptor status, n (%)
 ER positive 2217 (60) 145 (62)  
 PgR positive 1857 (50) 133 (57)  
 Either ER or PgR positive 2332 (63) 156 (67) 0.20
Additional adjuvant treatment, n (%)
 Endocrine therapy 2079 (56) 131 (56) 0.99
 Radiotherapy 2897 (78) 146 (63) <0.0001
  1. Total patient numbers may deviate from n = 3935 because of missing values for some characteristics
  2. ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PgR progesterone receptor, SD standard deviation